This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 18 print issues and online access
$259.00 per year
only $14.39 per issue
Rent or buy this article
Get just this article for as long as you need it
$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Dinah C, Greystoke B, Mueller I, Talks J. Action on sickle cell retinopathy: the time is now. Eye. 2022;36:1138–9.
UK National Screening Programme. Criteria for a population screening programme. 2022. https://www.gov.uk/government/publications/evidence-review-criteria-national-screening-programmes/criteria-for-appraising-the-viability-effectiveness-and-appropriateness-of-a-screening-programme/.
Downes SM, Hambleton IR, Chuang EL, Lois N, Serjeant GR, Bird AC. Incidence and natural history of proliferative sickle cell retinopathy: observations from a cohort study. Ophthalmology. 2005;112:1869–75.
NICE Technology appraisal guidance [TA743]. Crizanlizumab for preventing sickle cell crises in sickle cell disease. 2021. https://www.nice.org.uk/guidance/ta743/chapter/1-Recommendations/.
Author information
Authors and Affiliations
Contributions
Concept, draft and online submission: PTA; final draft and accuracy check: PTA, RS.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Ashwin, P.T., Sivaraj, R. Screening for sickle-cell retinopathy. Eye 37, 375 (2023). https://doi.org/10.1038/s41433-022-02199-9
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41433-022-02199-9